Companies/Ocular Therapeutix, Inc.

Company profile

Ocular Therapeutix, Inc.

NASDAQ: OCUL · Healthcare · Biotechnology

PublicHQ Bedford, MACIK 0001393434Reports USD

#428 of 1,394 Healthcare companies by revenue28th-percentile growth

EA Score

62C

FH 51DQ 86GM 39SS 73

v0.1 · 65/100 weight · provisional

↑ filing timeliness, market scale · ↓ Piotroski F, revenue growth (YoY)

Methodology →

Revenue TTM

$52.0M

Rev growth YoY (TTM)

-12.8%

Net income (FY)

-$265.9M

Employees

274

Market cap

$2.1B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$52.0M$52.0M2025

Net income-$265.9M-$265.9M2025

Operating income-$270.0M-$270.0M2025

Total assets$808.1M$808.1M2025

Liabilities$153.7M$153.7M2025

Equity$654.3M$654.3M2025

Revenue trend

FY2019 – FY2025 · USD

$829.0k

FY19

$4.2M

FY19

$17.4M

FY20

$43.5M

FY21

$51.5M

FY22

$58.4M

FY23

$63.7M

FY24

$52.0M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product100%

Collaboration revenue0%

By geography

Not disclosed.

The read

Ocular Therapeutix, Inc. booked $52.0M in FY2025 revenue, contracting 18% year over year — slower than 72% of Healthcare companies we track, at a -511.9% net margin.

Peers · Healthcare

UFP Technologies, Inc.80B+Nurix Therapeutics, Inc.53D ADMA Biologics, Inc.85A BioCryst Pharmaceuticals, Inc.76B+

Key facts

CEOPravin U. Dugel

SectorHealthcare

IndustryBiotechnology

HeadquartersBedford, MA

ExchangeNASDAQ: OCUL

Employees274

IPO date2014-07-25

Latest filings

8-K2026-06-12 8-K2026-05-05 10-Q2026-05-05 DEF 14A2026-04-30 8-K2026-02-27 8-K2026-02-05 10-K2026-02-05 8-K2026-01-23

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.